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ABSTRACT: The main aim of this work was to assess the occurrence and to characterize AmpC genes and to 
investigate the co-existence of 16S rRNA methylases and carbapenemases genes among the ESBL producing 
Escherichia coli strains. 180 Escherichia coli clinical strains were collected from the university hospital of 
Constantine located in the eastern part of Algeria. 42 ESBL-producers were phenotypically identified and also 
confirmed genotypically able to produce CTX-M-15 [n=33], CTX-M-1 [n=5], CTX-M-14 [n=1], SHV-2 [n=1], 
and two strains have been revealed producing the blaOXA-48 genes associated with blaTEM-1. Among the ESBL-
producing strains three expressed additionally an AmpC phenotype which corresponded to the carriage of a 
blaCMY gene shown by sequencing to correspond to CMY-2 (1 isolate) CMY-16 (2 isolates). The two E. coli 
isolates produce CMY-16 that belonged to phylogroup D while the single CMY-2 producing isolate belonged 
to phylogroup C. Antibiotic resistance of the aminoglycoside family by production of 16S rRNA methylases 
was detected by an end-point multiplex PCR assay which concerns genes coding for different 16S rRNA 
methylases (rmtD, rmtA, rmtB, armA, npmA, and rmtC). An armA gene was identified in 2 strains. This study 
shows for the first time the co-existance of CMY-16 and armA genes with blaTEM-1 and blaOXA-48 producing E. 
coli strains. 
Keywords: AmpC β-lactamase CMY-16; Escherichia coli; ArmA 16S rRNA methylases; ESBL coproduction. 
1. INTRODUCTION 
 The worldwide spread of genes conferring resistance to different antibiotics is considered as a major 
cause of mortality in hospitals [1]. Escherichia coli strains have been characterized by their resistance to 
antibiotics used in therapy [2]. The emergence of resistant strains to different families of antibiotics such as                  
β-lactams, and aminoglycosides pose a serious therapeutic problem in hospitals [3, 4]. In addition to the 
spread of β-lactam resistance, E. coli sequence type (ST131) has disseminated internationally and the strains  
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are considered to be truly pathogenic due to the spectrum of infectious they cause in both communities and 
hospitals [5]. 
 The resistance of E. coli strains to β-lactam antibiotics is rapidly disseminated and it is mainly related 
to the production of β-lactamases [6]. The production of AmpC is considered to be one of the mechanisms of 
resistance to β-lactam in the Enterobacteriaceae family, conferring resistance to all β-lactam antibiotics 
except fourth-generation cephalosporins and carbapenems [7]. The genes that code for these enzymes are of 
chromosome or plasmid origin [8]. The AmpC-lactamases were identified among Enterobacteriaceae, 
particularly in Escherichia coli, Salmonella enterica, Klebsiella pneumonia and Proteus mirabilis and also in 
naturally AmpC-producing species [9, 10]. The dissemination of resistance to aminoglycosides was also 
identified [11]. Aminoglycoside resistance by the production of 16S rRNA methylases is the most recognized 
type of resistance to these antibiotics [3, 12]. The first discovery of the armA gene occurred in 2003. Then, 
after the different studies, eight plasmid-mediated 16S rRNA methylases (rmtC, rmtA, armA, rmtE, 
rmtB, rmtD, npmA, and rmtF) were detected in clinical strains of gram negative bacilli [13, 14]. Currently, 
eleven 16S rRNA methylases genes (armA, rmtB, rmtD, rmtE, rmtC, rmtF, rmtA, npmA, rmtD2, rmtG and 
rmtH) have been identified, of which ArmA and RmtB were the most frequently found methylase in strains of 
 Enterobacteriaceae [15, 16]. 16S rRNA methyltransferase enzymes are generally seen together with 
carbapenemases and extended-spectrum beta-lactamase (ESBL). Coproduction of β-lactamase and 16S rRNA 
methylases among strains of Enterobacteriaceae leads to resistance to all treatment modalities [11, 16].   
 In this work we aimed to characterize the AmpC β-lactamase and 16S rRNA methylases among the 
ESBL and carbapenemases producing Escherichia coli. 
2. MATERIALS AND METHODS 
2.1. Collection of strains 
 180 E. coli strains were collected from patients hospitalized at the university hospital of Constantine 
Abdelhamid Ben Badis, Algeria. These samples were collected from different pathological humans’ 
specimens including wounds, pus, urine, blood and other body fluids such as gastric fluid and ascites fluid. 
These strains were characterized by standard bacteriological technique and the classic biochemical gallery and 
confirmed at the species level by the technique of MALDI-TOF MS (Matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry) by using Microflex LT (Bruker Daltonics, Germany) 
based on the MALDI BioTyper database (version IVD 2.2 DB-5989 MSP). 
2.2. In vitro antimicrobial sensitivity and phenotypic identification of resistance mechanisms 
 Antibiotic sensitivity testing was performed by the disk diffusion method on Mueller-Hinton agar and 
Microscan according to CLSI 2012 guidelines, for the following antibiotics: beta-lactam family (aztreonam, 
amoxicillin/clavulanate, ampicillin, cefotaxime, cefuroxime, ceftazidime, cefepime, piperacillin/tazobactam, 
temocillin, cefoxitin, ertapenem, meropenem), sulfonamides family (cotrimoxazole), quinolone family 
(ciprofloxacin), aminoglycoside family (amikacin and gentamicin). 
 All cefoxitin-resistant isolates (diameter of the inhibition zone <18 mm according to CLSI 2012) from 
this collection were selected for screening for AmpC genes. Extended-spectrum β-lactamase production has 
been detected by studying the resistance of the strains to third-generation cephalosporins and also by the 
double-disk synergy test.  
 Strains with reduced sensitivity to meropenem or ertapenem were identified phenotypically for the 
production of carbapenemase enzymes by Carba NP assay as previously reported by Nordmann et al. [17], the 
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modified Hodge test and the inhibition of the metallo-β-lactamase activity by ethylenediaminetetraacetic acid 
(EDTA) as previously described by Bakour et al., and Yong et al. [18, 19]. Aminoglycosides resistance 
induces the research of 16S rRNA methylases production in the isolates by detecting the genes involved in 
their biosynthesis.  
2.3. Extraction of DNA from bacterial strains  
 By the boiling lysis method, the DNA has been obtained. Suspensions of the analyzed strain and the 
control were prepared in 200 μL of sterile distilled water, boiled at (100ºC for 10 min and centrifuged at 
13’000 × g for 10 min). The supernatants were used as DNA template for PCR amplification assays [20]. 
2.4. Genotypic identification of ESBL, AmpC, 16S rRNA methylase and carbapenemase genes 
 Screening for genes encoding conventional ESBL (blaTEM, blaSHV, blaCTX-M), AmpC genes (CMY, FOX, 
ACC, MIR, ACT, MOX, DHA), carbapenemase genes (blaVIM, blaKPC, blaIMP, blaNDM, blaOXA-48) and the 16S 
rRNA methylases genes (armA, rmtA, rmtB, rmtC, rmtD, and npmA) was performed by an end-point 
multiplex PCR assay as previously described by Perez-Perez et al. and Bogaerts et al. [8, 20], followed by 
sequencing the PCR products such as (CTX-M, SHV, TEM, CMY). The products of the sequencing were 
compared to the sequences reported in Gen-Bank [21].  
2.5. Sequence type ST131 determination  
 Identification of the ST131 clone was carried out using O25b-ST131 clone allele-specific PCR for the 
papB gene [22]. 
2.6. Phylogenetic groups  
 The determination of phylogenetic groups of E. coli strains was performed by PCR method for phylo-
group assignment according to revised Clermont method. Each strain was assigned to one of eight major 
phylo-groups that are as follows (A, B1, B2, C, D, E, F, and clade I) [23].  
3. RESULTS  
3.1. Bacterial strains and ESBL producers 
 The double-disk synergy test for phenotypic detection of ESBL production revealed that 42 samples of 
E. coli (23%) produced ESBLs. The strains were mainly recovered from urine samples (60%), pus samples 
(30%) and those of other body fluids (10%).          
 Antibiotic resistance profile and sensitivity showed that all ESBL strains expressed resistance to 
multiple antimicrobial agents. The strains are highly resistant to ampicillin, cefuroxime, cefotaxime, cefepime 
and aztreonam. The strains resistance to other antibiotics was high for gentamicin (63%) ciprofloxacin (61%) 
and cotrimoxazole (60%) but low for amikacin (5%). The isolates showed a high sensitivity to piperacillin-
tazobactam (95%), ertapenem and meropenem with a frequency of (95%), temocillin (92%), cefoxitin (85%), 
amoxicillin-clavulanate (83%), and ceftazidime (66%) (Table 1). 
 According to CLSI 2012 recommendations, two isolates were obtained from two different patients 
urine samples were resistant to ertapenem (diameter of the inhibition zone < 18 mm) and to the majority of 
antibiotics used. However, these two strains exhibited intermediate resistance to meropenem and they were 
sensitivity to ciprofloxacin and cefepime. 
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Table 1. The antibiotic resistance and sensitivity profile of the ESBL strains of E. coli. 
Antibiotics 
ESBL  strains of E coli 
Phenotype Percentage % 
Ampicillin 
Resistant (R) 
 
100 
Cefuroxime 99 
Cefotaxime 99 
Cefepime 70 
Aztreonam 65 
Gentamicin 63 
Ciprofloxacin 61 
Cotrimoxazole 60 
Amikacin 5 
Piperacillin-Tazobactam 
Sensitive (S) 
95 
Ertapenem 95 
Meropenem 95 
Temocillin 92 
Cefoxitin 85 
Amoxicillin-clavulanate 83 
Ceftazidime 66 
 
3.2. Detection of carbapenemase production 
3.2.1. Carba NP test  
 Carba NP is a rapid test for screening carbapenemase producers in Enterobacteriaceae. In our study 
this assay is based on the ertapenem’s hydrolysis with a color change of a phenol indicator from red to orange 
or yellow (positive result) [17]. Only two strains of E. coli (E. coli 175, E. coli 178) were found to be 
producing carbapenemases (Figure 1).   
 
 
Figure 1. Carba NP test positive with two strains of E. coli OXA type; hydrolysis of ertapenem with a color change  
of a phenol indicator from red to orange or Yellow. From left to right the second tube is the one that is inoculated  
for (T+, T-, 175, 178). 
T+: positive control NDM positive E. coli; T-: negative control E. coli J53 
178: E. coli 1 (Ec1) carbapenemase positive; 175: E. coli 2 (Ec2) carbapenemase positive 
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3.2.2. Modified Hodge test 
 The presence of a carbapenemase is exposed by the deformation of the zone of inhibition due to the 
enzymatic activity around the antibiotic close to the suspect strain (Figure 2). By contrast, the EDTA test was 
observed negatively because the carbapenemases produced by these two strains of E. coli were not liked to 
NDM, VIM or IMP genes expression.     
 
 
Figure 2. Modified Hodge test positive with two strains of E. coli (Ec 175 and Ec 178); inactivation of carbapenem  
by carbapenemase-producing strains that enables a carbapenem-susceptible indicator strain to extend growth  
towards a carbapenem-containing disc, along the streak of inoculums of the tested suspected carbapenemase. 
 
3.3. Genotypic analysis of antibiotic resistance genes 
 The results of the end-point multiplex PCR and sequencing showed the presence of blaCTX-M in 39 
strains (5 blaCTX-M-1, 1 blaCTX-M-14, 33 blaCTX-M-15,) while blaSHV-2 was detected in one isolate and blaTEM-1 in two 
isolates. In addition the detection of AmpC gene like CMY-2 was showed in one strain of E. coli among the 
CTX-M-15 producing strains and the presence of CMY-16 in two strains of E. coli (TEM-1). These two strains 
have also been revealed to be producing carbapenemases (OXA-48) and 16S rRNA methylases (ArmA).  
3.4. Sequence type ST131 and phylogenetic groups determination  
 Detection of the ST131 clone using PCR targeting the papB gene revealed that 16 isolates (CTX-M-
15) were ST131 positive and that they belonged to phylogroup B2. While the other strains were ST131 
negative, among them two isolates (CTXM-15) belonged to group B2, two (CTXM-15) to group A, five 
(CTXM-1) to group B1, eight (CTXM-15) to group D, three (CTXM-15) to group C, two (CTXM-15) to 
group F, one (CTXM-14) to group D, one (SHV2) to group B1 and two (TEM-1) belonged to group D          
(Table 2).  
 
Table 2. Phylogenetic groups and sequence type ST131 of the ESBLs producing strains. 
Phylogenetic groups B2 A B1 D C F D 
ESBL type CTX-M-15 
CTX-
M-15 
CTX-
M-15 
CTX-
M-1 SHV-2 
CTX-
M-15 
CTX-
M-14 
CTX-
M-15 
CTX-
M-15 TEM-1 
ST131 Pos (+) Neg (-) Neg (-) Neg (-) Neg (-) Neg (-) Neg (-) Neg (-) Neg (-) Neg (-) 
Number 16 2 2 5 1 8 1 3 2 2 
Meziani et al.   Antibiotic resistance of CMY-16-producing Escherichia coli isolates 101 
European Journal of Biological Research 2020; 10(2): 96-104 
4. DISCUSSION 
 In our study, E. coli produced CTX-M15 that is the most common ESBL type, which confirms 
previous studies [24]. A similar situation is also observed in another country in North Africa in Morocco [25] 
which confirms the high dissemination of CTX-M15 producing E. coli isolates. Comparing to other studies 
[26], our study confirms the dissemination of E. coli ST131 associated with the CTX-M-15 Extended-
Spectrum beta-lactamase and attests the serious worldwide problem of multidrug-resistant pathogen E. coli 
strains.  
 CTX-M1, CTX-M14, TEM-1, SHV-2 and OXA-48 genes were detected in E. coli strains identified in 
this study have been also mentioned in previous findings [25, 27]. Nevertheless, the SHV-2 ESBL that was 
identified in this study was never described to date among E. coli clinical isolates in Algeria, but one study 
revealed the detection of SHV-12 ESBL in clinical strains of E. coli isolated from hospitals in the west of 
Algeria [27].  
 The armA gene which was detected in our analyzed strains was identified previously in 2016. A report 
from the west of Algeria [27] had revealed that there were four ArmA producers among E. coli strains which 
were gathered from some hospitals in the western part of Algeria. 
 Concerning the AmpC β-lactamase production in this study, the sequence analysis, showed that blaCMY 
genes detected were blaCMY-2 (one isolate) and blaCMY-16 (two isolates). The CMY-2 type is the most frequent, 
especially in Europe (France, Spain, Italy, and Turkey [28, 29], in Canada, Argentina, Tunisia and Algeria [27, 
30, 31]. So, our results are consistent with the previous results.  
 CMY-16, a variant of the CMY lineage was first detected in Proteus mirabilis that was isolated from 
Italy [32] and since then it has been detected throughout the world. CMY-16 was found to be the most 
prevalent variant of AmpC β-lactamases in Europe [33]. A study in Italy demonstrated the co-existance of 
CMY-16   in association with TEM-92 which is an ESBL in Proteus mirabilis isolates [34]. Similarily as in 
another study in Croatia, CMY-16 was found in Proteus mirabilis in association with TEM-1 [35]. In 
Switzerland CMY-16 was detected in association with OXA-48, CTXM-15 and ArmA [36] in Klebsiella 
pneumonia strains. As well as, In Tunisia they have reported the coproduction of CMY-16 and OXA-1 in           
E. coli strains [37].   
 Here, in our study we report the first detection of CMY-16 gene in association with TEM-1 BLSE, 
OXA-48 carbapenemase and ArmA 16S rRNA methylases in E. coli strains. The combination reported in this 
study was not described before: two strains of E. coli CMY-16 co-produced TEM-1 plus OXA-48 and ArmA. 
The phylogenetic study showed that these two strains belonged to phylogenetic group D and they were ST131 
negative. In fact they were collected from two different patients. 
 So, the dissemination of CMY-16 and armA genes detected in carbapenemase-ESBL producing E. coli 
clinical samples is a major problem. The emergence of this resistant type should be controlled and limited 
through molecular surveillance. 
5. CONCLUSION 
 According to data published, we describe here the first detection of multiresistant isolates of E. coli 
that co-produced: CMY-16, TEM-1, OXA-48 and ArmA. Our study confirms the major problem of multi-
resistance of E. coli strains. The association of multiple resistance genes in E. coli strains is a disturbing 
situation. So, there is a need to detect and to control their dissemination by creating new treatments to contain 
the risk of spread. 
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